Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

February 2, 2023

GSK receives orphan drug designation for Benlysta to treat systemic sclerosis

GSK has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its B-cell inhibiting monoclonal antibody Benlysta (belimumab) to potentially treat systemic sclerosis (SSc).

GSK receives orphan drug designation for Benlysta to treat systemic sclerosis